Last reviewed · How we verify
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Details
| Lead sponsor | Daiichi Sankyo |
|---|---|
| Phase | PHASE3 |
| Status | RECRUITING |
| Enrolment | 710 |
| Start date | Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Mar 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Endometrial Cancer
Interventions
- Trastuzumab Deruxtecan
- Chemotherapy
Countries
Japan, Taiwan, South Korea, China, United States